NDA/PLA REVIEWS MAY NOT BE DELAYED DUE TO GENERAL DATA INTEGRITY ISSUES UNDER PhRMA FDA REFORM PLAN; OTC OFFICE WOULD RETURN TO REVIEW ALL SWITCHES

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".